Literature DB >> 27068425

Gardasil Vaccination for Recurrent Laryngeal Papillomatosis in Adult Men: First Report: Changes in HPV Antibody Titer.

Kiyoshi Makiyama1, Ryoji Hirai2, Hiroumi Matsuzaki2.   

Abstract

BACKGROUND: Patients with human papillomavirus (HPV) DNA-positive recurrent laryngeal papillomatosis commonly have repeated recurrences following surgery. The reason is suspected to be a mechanism by which latent HPV infection in the surrounding healthy mucosa reinfects the surgical site. It may be that production of HPV antibodies in the laryngeal mucosa with Gardasil injection could inhibit postoperative recurrence. STUDY
DESIGN: This is a case series study.
PURPOSE: The purpose of this study was to examine whether Gardasil injection effectively inhibits recurrence. However, as a first report, we describe the antibody titers before and after vaccination.
METHODS: Gardasil was injected in 12 men (aged 32-74 years; mean age 47.9 years) with HPV-positive laryngeal papillomatosis. Serum antibody titers of HPV-6, -11, -16, and -18 were measured by a competitive Luminex-based immunoassay before the vaccination and 7 months after the start of the vaccination.
RESULTS: Each of the antibody titers was very low before vaccination, and they rose in all patients after the vaccination.
CONCLUSIONS: This finding demonstrates that antibody titers increase with Gardasil injection in post-adolescent males.
Copyright © 2017 The Voice Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Gardasil; antibody titers; quadrivalent HPV vaccine; recurrent laryngeal papilloma; recurrent respiratory papillomatosis

Mesh:

Substances:

Year:  2016        PMID: 27068425     DOI: 10.1016/j.jvoice.2016.01.008

Source DB:  PubMed          Journal:  J Voice        ISSN: 0892-1997            Impact factor:   2.009


  6 in total

1.  HPV vaccine awareness and the association of trust in cancer information from physicians among males.

Authors:  Dexter L Cooper; Natalie D Hernandez; Latrice Rollins; Tabia Henry Akintobi; Calvin McAllister
Journal:  Vaccine       Date:  2017-04-07       Impact factor: 3.641

Review 2.  Current and future management of recurrent respiratory papillomatosis.

Authors:  Ryan Ivancic; Hassan Iqbal; Brad deSilva; Quintin Pan; Laura Matrka
Journal:  Laryngoscope Investig Otolaryngol       Date:  2018-01-14

3.  In RRP, serologic response to HPV is frequently absent and slow to develop.

Authors:  Farrel J Buchinsky; Nicole Ruszkay; William Valentino; Craig S Derkay; John E McClay; Robert W Bastian; Charles M Myer; Kevin W Lollar; Dalya Guris
Journal:  PLoS One       Date:  2020-03-11       Impact factor: 3.240

Review 4.  Recurrent respiratory papillomatosis: A 2020 perspective.

Authors:  Jacob J Benedict; Craig S Derkay
Journal:  Laryngoscope Investig Otolaryngol       Date:  2021-03-13

5.  Recurrent respiratory papillomatosis (RRP)-time for a reckoning?

Authors:  Peter Kin Cho Goon; Lars-Uwe Scholtz; Holger Sudhoff
Journal:  Laryngoscope Investig Otolaryngol       Date:  2017-05-28

6.  Immune Therapy Targeting E6/E7 Oncogenes of Human Paillomavirus Type 6 (HPV-6) Reduces or Eliminates the Need for Surgical Intervention in the Treatment of HPV-6 Associated Recurrent Respiratory Papillomatosis.

Authors:  Charu Aggarwal; Roger B Cohen; Matthew P Morrow; Kimberly A Kraynyak; Albert J Sylvester; Jocelyn Cheung; Kelsie Dickerson; Veronique Schulten; Dawson Knoblock; Elisabeth Gillespie; Joshua M Bauml; Jian Yan; Malissa Diehl; Jean Boyer; Michael Dallas; J Joseph Kim; David B Weiner; Jeffrey M Skolnik
Journal:  Vaccines (Basel)       Date:  2020-01-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.